Abstract
IORT is a powerful tool for the management of cancer and has been shown to improve local control in the treatment of sarcomas in one prospective, randomized, controlled trial. IORT allows dose escalation in areas where escalation with EBRT would cause potentially excessive acute or late normal tissue toxicity. It has a unique toxicity profile but remains safe and effective when used in appropriately selected patients. In addition, IORT is becoming more widely available at different cancer centers and offers great flexibility in treatment planning for a wide variety of malignancies. As IORT use becomes more common, special care will be required to ensure that it is used by a multidisciplinary team of radiation oncologists and surgeons to ensure the best results for patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1015-1029 |
| Number of pages | 15 |
| Journal | Surgical Oncology Clinics of North America |
| Volume | 12 |
| Issue number | 4 |
| DOIs | |
| State | Published - Oct 2003 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Surgery
- Oncology
Fingerprint
Dive into the research topics of 'Intraoperative radiotherapy in the multimodality approach to bone and soft tissue cancers'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver